| Identification | Back Directory | [Name]
1-Piperidinecarboxamide, 4-(1,2-dihydro-2-oxo-3-quinolinyl)-N-[(1R)-1-[(7-methyl-1H-indazol-5-yl)methyl]-2-[4-(1-methyl-4-piperidinyl)-1-piperazinyl]-2-oxoethyl]- | [CAS]
1337918-83-8 | [Synonyms]
BHV-3500
Vazegepant
Zavegepant
Vazegepant free base
Zavegepant (BHV-3500, BMS-742413)
1-Piperidinecarboxamide, 4-(1,2-dihydro-2-oxo-3-quinolinyl)-N-[(1R)-1-[(7-methyl-1H-indazol-5-yl)methyl]-2-[4-(1-methyl-4-piperidinyl)-1-piperazinyl]-2-oxoethyl]- | [Molecular Formula]
C36H46N8O3 | [MDL Number]
MFCD27938555 | [MOL File]
1337918-83-8.mol | [Molecular Weight]
638.8 |
| Chemical Properties | Back Directory | [Boiling point ]
933.7±65.0 °C(Predicted) | [density ]
1.285±0.06 g/cm3(Predicted) | [form ]
Solid | [pka]
11.68±0.70(Predicted) | [color ]
White to off-white |
| Hazard Information | Back Directory | [Uses]
Vazegepant (Zavegepant) is an orally active calcitonin gene-related peptide CGRP receptor antagonist with potential for acute research in migraine, can be administered intranasally. CGRP is an important trigger in migraine pathophysiology[1][2][3][4]. | [References]
[1] Moreno-Ajona D, et al. Gepants, calcitonin-gene-related peptide receptor antagonists: what could be their role in migraine treatment? Curr Opin Neurol. 2020 Jun;33(3):309-315. DOI:10.1097/WCO.0000000000000806
[2] Gene M Dubowchik, et al. Blocking the CGRP Pathway for Acute and Preventive Treatment of Migraine: The Evolution of Success. DOI:10.1021/acs.jmedchem.9b01810
[3] Capi M, De Angelis V, De Bernardini D, et al. Zavegepant[M]//Novel Synthetic Drugs in Migraine. Cham: Springer International Publishing, 2022: 67-72.
[4] Jéssica Barreto Ribeiro Dos Santos, et al. Small-molecule CGRP receptor antagonists: A new approach to the acute and preventive treatment of migraine. Eur J Pharmacol.2022 May 5:922:174902. DOI:10.1016/j.ejphar.2022.174902 |
|
|